Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited Janssen, the company manufacturing abiraterone acetate (AA; tradename Zytiga(®)), to submit evidence for the clinical and cost effectiveness of AA in combination with prednisone/prednisolone (AAP) compared with watchful waiting (i....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pharmacoeconomics
Egile Nagusiak: Ramaekers, Bram L. T., Riemsma, Rob, Tomini, Florian, van Asselt, Thea, Deshpande, Sohan, Duffy, Steven, Armstrong, Nigel, Severens, Johan L., Kleijnen, Jos, Joore, Manuela A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer International Publishing 2016
Gaiak:
Review Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5253156/
https://ncbi.nlm.nih.gov/pubmed/27566699
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-016-0445-5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak